Drug name: Trastuzumab + XL147


Related CSCTT Targets

ERBB2 [ref.1]P04626

Trastuzumab

Cas.no PubChem ID
180288-69-1
Known Target
Receptor tyrosine-protein kinase erbB-2P04626
Structure
...
Introduction
Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab is also being studied for the treatment of other cancers. It has been used with some success in women with uterine papillary serous carcinomas that overexpress HER2/neu.

XL147

Cas.no PubChem ID
956958-53-5 1893730
Known Target
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformP42336
Structure
...
Introduction
XL147 is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In preclinical studies, XL147 slowed tumor growth or caused tumor shrinkage in multiple preclinical cancer models, including breast, lung, ovarian, and prostate cancers, and gliomas. XL147 has also been shown to enhance the anti- tumor effects of several chemotherapeutic agents and an inhibitor of epidermal growth factor receptor (EGFR) in preclinical cancer models.

Reference

  • [1] Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Chakrabarty, A., et al. (2013).Cancer Res.73(3):1190-200.
    23204226. [ 23204226 ]

Back to top